Bioxytran (BIXT) director buys 210K common shares at $0.60
Bioxytran, Inc. (BIXT) reported insider share purchases by director Alan Hoberman.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Bioxytran, Inc. (BIXT) reported insider share purchases by director Alan Hoberman. On 08/12/2025, he acquired 10,417 shares of preferred stock at $0.485 per share, bringing his preferred holdings to 377,619 shares. On 11/14/2025, he bought an additional 38,588 preferred shares at $0.35 per share, increasing his total preferred holdings to 416,207 shares. On 11/18/2025, he purchased 210,000 shares of common stock at $0.60 per share and held 210,000 common shares afterward. All positions are reported as held directly by the insider.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | common | 210,000 | $0.60 | $126K |
| Grant/Award | preferred | 38,588 | $0.35 | $14K |
| Grant/Award | preferred | 10,417 | $0.485 | $5K |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions were reported for BIOXYTRAN, INC (BIXT)?
The filing reports that director Alan Hoberman acquired preferred shares on 08/12/2025 and 11/14/2025, and common shares on 11/18/2025, all in open-market style purchases.
What is the relationship of the reporting person to BIOXYTRAN, INC (BIXT)?
The reporting person, Alan Hoberman, is identified as a director of BIOXYTRAN, INC.
AI-generated analysis. How Rhea-AI works. Not financial advice.